We advised the initial purchasers on the Rule 144A / Regulation S notes offering

Davis Polk advised the representatives of the several initial purchasers in connection with a Rule 144A / Regulation S offering of $850 million aggregate principal amount of 1.875% notes due 2026 and $650 million aggregate principal amount of 3.000% notes due 2031 by Fresenius Medical Care US Finance III, Inc. The notes are guaranteed by Fresenius Medical Care AG & Co. KGaA and Fresenius Medical Care Holdings, Inc.

Fresenius Medical Care is the world’s largest kidney dialysis company. Through its network of over 4,000 dialysis clinics, Fresenius Medical Care provides dialysis treatments for more than 340,000 patients around the globe.

The Davis Polk corporate team included partner Leo Borchardt, counsel Radoslaw Michalak and associate Saratu M. Kitchener. Counsel Alon Gurfinkel and associate Omer Harel provided U.S. tax advice. Counsel Will Schisa provided sanctions advice. Counsel Charles Shi provided ERISA advice. The English law team included European counsel John Taylor and associate Mark Chalmers. Members of the Davis Polk team are based in the London, New York and Washington DC offices.

Copy link to share post